Key points are not available for this paper at this time.
Performance of 18F-DCFPyL-PET/CT achieved the study's primary endpoint, demonstrating disease localization in the setting of negative standard imaging and providing clinically meaningful and actionable information. These data further support the utility of 18F-DCFPyL-PET/CT to localize disease in men with recurrent prostate cancer.See related commentary by True and Chen, p. 3512.
Building similarity graph...
Analyzing shared references across papers
Loading...
Michael J. Morris
Memorial Sloan Kettering Cancer Center
Steven P. Rowe
University of North Carolina at Chapel Hill
Michael A. Gorin
Mount Sinai Health System
Clinical Cancer Research
Stanford University
University of Michigan
Johns Hopkins University
Building similarity graph...
Analyzing shared references across papers
Loading...
Morris et al. (Tue,) studied this question.
synapsesocial.com/papers/69d73d2b8e958094d1b8a679 — DOI: https://doi.org/10.1158/1078-0432.ccr-20-4573